

09/676,032

(FILE 'HOME' ENTERED AT 23:09:53 ON 02 NOV 2001)

FILE 'STNGUIDE' ENTERED AT 23:10:02 ON 02 NOV 2001

FILE 'REGISTRY' ENTERED AT 23:12:31 ON 02 NOV 2001

L1 STRUCTURE UPLOADED

L2 108 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 23:13:40 ON 02 NOV 2001

L3 4 S L2

FILE 'STNGUIDE' ENTERED AT 23:16:52 ON 02 NOV 2001

=>


09/676,032

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 23:13:23 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 250 TO ITERATE

100.0% PROCESSED 250 ITERATIONS

108 ANSWERS

SEARCH TIME: 00.00.01

L2 108 SEA SSS FUL L1

=> file caplus


09/676,032

=> s 12

L3 4 L2

=> d 13 abs ibib hitstr 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2001 ACS
GI



AB A pharmaceutical compn. that is effective in the treatment of HIV and other viral infections and inhibits growth of cancers and tumors in mammals comprises a benzimidazole deriv. (I; R = H, CO₂H, OH, NH₂, CO₂R₁; R₁ = alkoxy, haloalkyl, alkenyl, cycloalkyl), the pharmaceutically acceptable salts thereof, or mixts. thereof. I (R = H) inhibits the growth of B16 murine melanoma and HT29 human colon carcinoma cells with IC₅₀ of 4.925 and 3.297 .mu.M, resp.

ACCESSION NUMBER: 1998:764283 CAPLUS
DOCUMENT NUMBER: 130:20597
TITLE: Benzimidazole-2-carbamates for the treatment of viral infections and cancer
INVENTOR(S): Camden, James Berger
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851304	A1	19981119	WO 1997-US21565	19971126
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874027	A1	19981208	AU 1998-74027	19971126
AU 728690	B2	20010118		
EP 956017	A1	19991117	EP 1997-949600	19971126
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
BR 9714634	A	20000523	BR 1997-14634	19971126
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
PRIORITY APPLN. INFO.:			US 1997-857811 A	19970516
			WO 1997-US21565 W	19971126

Delacroix

09/676,032

WO 1997-US24565 W 19971126

OTHER SOURCE(S): MARPAT 130:20597


IT 216148-83-3 216148-85-5 216148-87-7

216148-88-8 216148-89-9 216148-90-2

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (benzimidazole-2-carbamates for treatment of cancer and viral infections)


RN 216148-83-3 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester (9CI) (CA INDEX NAME)




RN 216148-85-5 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester (9CI) (CA INDEX NAME)



RN 216148-87-7 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester (9CI) (CA INDEX NAME)



RN 216148-88-8 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester (9CI) (CA INDEX NAME)

09/676,032




RN 216148-89-9 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester (9CI) (CA INDEX NAME)



RN 216148-90-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)



IT 216148-91-3 216148-94-6 216148-95-7
216148-96-8 216148-98-0 216149-00-7
216149-02-9 216149-09-6 216149-10-9
216149-11-0 216149-13-2 216149-14-3
216149-16-5 216149-17-6 216149-18-7
216149-19-8 216149-20-1 216149-21-2
216149-22-3 216149-23-4 216149-27-8
216149-29-0 216149-31-4 216149-33-6
216149-35-8 216149-37-0 216149-43-8
216149-45-0 216149-47-2 216149-53-0
216149-56-3 216149-59-6 216149-62-1
216149-69-8 216149-72-3 216149-74-5
216149-77-8 216149-81-4 216149-84-7
216149-85-8 216149-87-0 216149-88-1
216149-91-6 216149-92-7 216149-95-0
216149-96-1 216149-98-3 216149-99-4
216150-01-5 216150-02-6 216150-03-7
216150-04-8 216150-06-0 216150-07-1
216150-08-2 216150-09-3 216150-10-6
216150-12-8 216150-17-3 216150-19-5
216150-20-8 216150-21-9 216150-22-0
216150-23-1 216150-27-5 216150-28-6
216150-30-0 216150-31-1 216150-32-2

Delacroix

09/676,032

216150-34-4 216150-35-5 216150-40-2


216150-41-3 216150-42-4 216150-43-5

216150-44-6 216150-45-7 216150-46-8

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(benzimidazole-2-carbamates for treatment of cancer and viral
infections)

RN 216148-91-3 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216148-94-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216148-95-7 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-83-3

CMF C14 H16 Cl N3 O4



Delacroix


09/676,032



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216148-96-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 7697-37-2

CMF H N O3



RN 216148-98-0 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

Delacroix


09/676,032

CRN 216148-83-3
CMF C14 H16 Cl N3 O4



CM 2


CRN 7664-38-2
CMF H3 O4 P



RN 216149-00-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-83-3
CMF C14 H16 Cl N3 O4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 216149-02-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,

Delacroix


09/676,032

4-chlorobutyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3

CMF C14 H16 Cl N3 O4




CM 2

CRN 87-69-4

CMF C4 H6 O6

CDES 1:R2:R*,R*

Absolute stereochemistry.




RN 216149-09-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3

CMF C14 H16 Cl N3 O4



CM 2

CRN 110-16-7


CMF C4 H4 O4

Delacroix

09/676,032

CDES 2:Z


Double bond geometry as shown.



RN 216149-10-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA
INDEX NAME)


CM 1

CRN 216148-83-3
CMF C14 H16 Cl N3 O4



CM 2

CRN 77-92-9
CMF C6 H8 O7




RN 216149-11-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
4-chlorobutyl ester, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3
CMF C14 H16 Cl N3 O4


09/676,032



CM 2

CRN 65-85-0

CMF C7 H6 O2




RN 216149-13-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 4-chlorobutyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3


CMF C14 H16 Cl N3 O4



CM 2

CRN 69-72-7

CMF C7 H6 O3



RN 216149-14-3 CAPLUS

CN L-Ascorbic acid, compd. with 4-chlorobutyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)


Delacroix

09/676,032

CM 1

CRN 216148-83-3

CMF C14 H16 Cl N3 O4




CM 2

CRN 50-81-7

CMF C6 H8 O6

CDES 5:L-THREO

Absolute stereochemistry.




RN 216149-16-5 CAPLUS

CN Butanedioic acid, hydroxy-, compd. with 4-chlorobutyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-83-3

CMF C14 H16 Cl N3 O4




CM 2

CRN 6915-15-7

CMF C4 H6 O5


Delacroix

09/676,032



RN 216149-17-6 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216149-18-7 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216149-19-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-85-5

CMF C16 H21 N3 O6



Delacroix


09/676,032



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216149-20-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5


CMF C16 H21 N3 O6



CM 2

CRN 7697-37-2

CMF H N O3



RN 216149-21-2 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid; 2-[(methoxycarbonyl)amino]-, 2-(2-ethoxyethoxy)ethyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

Delacroix


09/676,032

CRN 216148-85-5
CMF C16 H21 N3 O6



CM 2


CRN 7664-38-2
CMF H3 O4 P



RN 216149-22-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-[(2-ethoxyethoxy)ethyl] ester, monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-85-5
CMF C16 H21 N3 O6



CM 2

CRN 64-18-6
CMF C H2 O2



RN 216149-23-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,

Delacroix


09/676,032

2-(2-ethoxyethoxy)ethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI)
(CA INDEX NAME)

CM 1

CRN 216148-85-5

CMF C16 H21 N3 O6




CM 2

CRN 87-69-4

CMF C4 H6 O6

CDES 1:R2:R*,R*

Absolute stereochemistry.




RN 216149-27-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5

CMF C16 H21 N3 O6



CM 2

CRN 110-16-7


CMF C4 H4 O4

Delacroix

09/676,032

CDES 2:Z


Double bond geometry as shown.



RN 216149-29-0 CAPLUS
CN Butanedioic acid, hydroxy-, compd. with 2-(2-ethoxyethoxy)ethyl
2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-85-5
CMF C16 H21 N3 O6



CM 2

CRN 6915-15-7
CMF C4 H6 O5




RN 216149-31-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI)
(CA INDEX NAME)

CM 1

CRN 216148-85-5
CMF C16 H21 N3 O6

Delacroix


09/676,032



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 216149-33-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(2-ethoxyethoxy)ethyl ester, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5


CMF C16 H21 N3 O6



CM 2

CRN 65-85-0

CMF C7 H6 O2



RN 216149-35-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,

Delacroix


09/676,032

2-(2-ethoxyethoxy)ethyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5


CMF C16 H21 N3 O6



CM 2

CRN 69-72-7

CMF C7 H6 O3




RN 216149-37-0 CAPLUS

CN L-Ascorbic acid, compd. with 2-(2-ethoxyethoxy)ethyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-85-5

CMF C16 H21 N3 O6



CM 2

CRN 50-81-7


CMF C6 H8 O6

CDES 5:L-THREO

Absolute stereochemistry.


Delacroix

09/676,032



RN 216149-43-8 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216149-45-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 216149-47-2 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7

CMF C14 H15 N3 O4


09/676,032



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 216149-53-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 7697-37-2

CMF H N O3



RN 216149-56-3 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

Delacroix


09/676,032

CRN 216148-87-7
CMF C14 H15 N3 O4



CM 2


CRN 7664-38-2
CMF H3 O4 P



RN 216149-59-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 216148-87-7
CMF C14 H15 N3 O4



CM 2

CRN 64-18-6
CMF C H2 O2



RN 216149-62-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl

Delacroix


09/676,032

ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7

CMF C14 H15 N3 O4




CM 2

CRN 87-69-4

CMF C4 H6 O6

CDES 1:R2:R*,R*

Absolute stereochemistry.




RN 216149-69-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7

CMF C14 H15 N3 O4



CM 2

CRN 110-16-7


CMF C4 H4 O4

CDES 2:Z

Delacroix

09/676,032


Double bond geometry as shown.



RN 216149-72-3 CAPLUS
CN Butanedioic acid, hydroxy-, compd. with 3-butenyl 2-
[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-87-7
CMF C14 H15 N3 O4



CM 2


CRN 6915-15-7
CMF C4 H6 O5



RN 216149-74-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl
ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7
CMF C14 H15 N3 O4




Delacroix

09/676,032

CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 216149-77-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7


CMF C14 H15 N3 O4



CM 2

CRN 65-85-0

CMF C7 H6 O2



RN 216149-81-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-butenyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)


CM 1

CRN 216148-87-7

CMF C14 H15 N3 O4

Delacroix


09/676,032



CM 2

CRN 69-72-7

CMF C7 H6 O3




RN 216149-84-7 CAPLUS

CN L-Ascorbic acid, compd. with 3-butenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-87-7

CMF C14 H15 N3 O4




CM 2

CRN 50-81-7

CMF C6 H8 O6

CDES 5:L-THREO

Absolute stereochemistry.




Delacroix

09/676,032

RN 216149-85-8 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216149-87-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216149-88-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8

CMF C21 H29 N3 O4




CM 2

CRN 7664-93-9

CMF H2 O4 S

09/676,032




RN 216149-91-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 7697-37-2

CMF H N O3




RN 216149-92-7 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8

CMF C21 H29 N3 O4




Delacroix

09/676,032

CM 2

CRN 7664-38-2

CMF H3 O4 P




RN 216149-95-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 64-18-6

CMF C H2 O2



RN 216149-96-1 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8

CMF C21 H29 N3 O4

09/676,032




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.




RN 216149-98-3 CAPLUS

CN Butanedioic acid, hydroxy-, compd. with 3,3,7-trimethyl-6-octenyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 6915-15-7

CMF C4 H6 O5



RN 216149-99-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,3,7-trimethyl-6-octenyl ester, 2-hydroxy-1,2,3-propanetricarboxylate

Delacroix


09/676,032

(9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8


CMF C21 H29 N3 O4



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 216150-01-5 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-88-8

CMF C21 H29 N3 O4




CM 2

CRN 65-85-0

CMF C7 H6 O2

Delacroix


09/676,032



RN 216150-02-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-88-8
CMF C21 H29 N3 O4



CM 2


CRN 69-72-7
CMF C7 H6 O3



RN 216150-03-7 CAPLUS
CN L-Ascorbic acid, compd. with 3,3,7-trimethyl-6-octenyl
2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-88-8
CMF C21 H29 N3 O4



Delacroix

09/676,032




CM 2

CRN 50-81-7

CMF C6 H8 O6


CDES 5:L-THREO

Absolute stereochemistry.



RN 216150-04-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 216150-06-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, monohydrobromide (9CI) (CA INDEX NAME)

Delacroix

09/676,032



● HBr


RN 216150-07-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 216150-08-2 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9

CMF C15 H17 N3 O4


09/676,032



CM 2

CRN 7697-37-2

CMF H N O3




RN 216150-09-3 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 216150-10-6 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

Delacroix

09/676,032

CRN 216148-89-9
CMF C15 H17 N3 O4



CM 2


CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 216150-12-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA
INDEX NAME)

CM 1


CRN 216148-89-9
CMF C15 H17 N3 O4



CM 2


CRN 87-69-4
CMF C4 H6 O6
CDES 1:R2:R*,R*

Absolute stereochemistry.



Delacroix


09/676,032



RN 216150-17-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-89-9
CMF C15 H17 N3 O4



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.




RN 216150-19-5 CAPLUS
CN Butanedioic acid, hydroxy-, compd. with 1-cyclopropylethyl
2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)

CM 1

CRN 216148-89-9
CMF C15 H17 N3 O4


09/676,032



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 216150-20-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI) (CA
INDEX NAME)

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 216150-21-9 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, monobenzoate (9CI) (CA INDEX NAME)


Delacroix

09/676,032

CM 1

CRN 216148-89-9


CMF C15 H17 N3 O4



CM 2

CRN 65-85-0

CMF C7 H6 O2




RN 216150-22-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-cyclopropylethyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9

CMF C15 H17 N3 O4




CM 2

CRN 69-72-7

CMF C7 H6 O3

Delacroix

09/676,032




RN 216150-23-1 CAPLUS

CN L-Ascorbic acid, compd. with 1-cyclopropylethyl 2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216148-89-9

CMF C15 H17 N3 O4




CM 2

CRN 50-81-7

CMF C6 H8 O6


CDES 5:L-THREO

Absolute stereochemistry.



RN 216150-27-5 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

Delacroix


09/676,032



● HCl

RN 216150-28-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 216150-30-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2

CMF C18 H25 N3 O4




CM 2

CRN 7664-93-9

CMF H2 O4 S

Delacroix

09/676,032




RN 216150-31-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 7697-37-2

CMF H N O3




RN 216150-32-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, phosphate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2

CMF C18 H25 N3 O4




CM 2

Delacroix

09/676,032

CRN 7664-38-2

CMF H3 O4 P




RN 216150-34-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 64-18-6

CMF C H2 O2




RN 216150-35-5 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,4,4-trimethylpentyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI) (CA INDEX NAME)

CM 1


CRN 216148-90-2

CMF C18 H25 N3 O4



Delacroix

09/676,032




CM 2

CRN 87-69-4

CMF C4 H6 O6

CDES 1:R2:R*,R*

Absolute stereochemistry.




RN 216150-40-2 CAPLUS

CN Butanedioic acid, hydroxy-, compd. with 2,4,4-trimethylpentyl
2-[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 6915-15-7

CMF C4 H6 O5



RN 216150-41-3 CAPLUS

Delacroix


09/676,032

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (9CI)
(CA INDEX NAME)

CM 1

CRN 216148-90-2


CMF C18 H25 N3 O4



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 216150-42-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2

CMF C18 H25 N3 O4




CM 2

CRN 65-85-0

CMF C7 H6 O2

Delacroix


09/676,032



RN 216150-43-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, mono(2-hydroxybenzoate) (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-90-2
CMF C18 H25 N3 O4



CM 2


CRN 69-72-7
CMF C7 H6 O3



RN 216150-44-6 CAPLUS
CN L-Ascorbic acid, compd. with 2,4,4-trimethylpentyl 2-
[(methoxycarbonyl)amino]-1H-benzimidazole-5-carboxylate (9CI) (CA INDEX
NAME)


CM 1

CRN 216148-90-2
CMF C18 H25 N3 O4



Delacroix

09/676,032




CM 2

CRN 50-81-7

CMF C6 H8 O6

CDES 5:L-THREO

Absolute stereochemistry.




RN 216150-45-7 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2,4,4-trimethylpentyl ester, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216148-90-2

CMF C18 H25 N3 O4




CM 2

CRN 110-16-7

CMF C4 H4 O4


CDES 2:Z

Double bond geometry as shown.



Delacroix


09/676,032



RN 216150-46-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,3,7-trimethyl-6-octenyl ester, (2R,3R)-2,3-dihydroxybutanedioate (9CI)
(CA INDEX NAME)

CM 1


CRN 216148-88-8
CMF C21 H29 N3 O4



CM 2

CRN 87-69-4
CMF C4 H6 O6
CDES 1:R2:R*,R*

Absolute stereochemistry.




REFERENCE COUNT: 3
REFERENCE(S): (1) Ernest, L; Biochem Pharmacol 1985, V34(19), P3603
(2) Siya, R; J Med Chem 1995, V35, P539
(3) The Procter & Gamble Company; WO 9632107 A 1996
CAPLUS

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2001 ACS
AB The design and synthesis of a series of Me 5(6)-substituted
benzimidazole-2-carbamates as potential anthelmintics are described. A
rational anal. of the structural parameters which segregate the activity
of resulting benzimidazole-2-carbamates against enteric and tissue
dwelling helminths is presented. The influence of single and multiple
spacers, which link the pharmacophores at 5(6)-position of
benzimidazole-2-carbamate, on the activity against *Ancylostoma ceylanicum*
(hookworm), *Syphacia obvelata* (pinworm), *Hymenolepis nana* (tapeworm)


Delacroix

Litomosoides carinii and *Acanthocheilonema viteae* (filarial worm) has been presented. This anal. indicates that for activity against intestinal helminth the presence of one spacer holding the pharmacophore approx. 3 .ANG. apart from the parent nucleus is usually preferred. While for activity against tissue dwelling parasite, the repetition of the benzimidazole-2-carbamate nucleus joined together through the 5,5'-position with one spacer kept apart by distance of 3 .ANG. unit is usually desired.

ACCESSION NUMBER: 1994:124172 CAPLUS
 DOCUMENT NUMBER: 120:124172
 TITLE: Segregation of activity profile in benzimidazoles: effect of spacers at 5(6)-position of methyl benzimidazole-2-carbamates
 AUTHOR(S): Agarwal, Shiv K.; Sharma, Satyavan; Bhaduri, A. P.
 CORPORATE SOURCE: Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, 226001, India
 SOURCE: Z. Naturforsch., C: Biosci. (1993), 48(11-12), 829-38
 CODEN: ZNCBDA; ISSN: 0341-0382
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 121649-63-6 121649-65-8 121649-66-9
 153213-39-9 153213-40-2 153213-41-3
 153213-42-4
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anthelmintic activity of, structure-activity relations in)
 RN 121649-63-6 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 121649-65-8 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, propyl ester (9CI) (CA INDEX NAME)




RN 121649-66-9 CAPLUS
 CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

09/676,032




RN 153213-39-9 CAPLUS

CN Carbamic acid, [5-[[[4-benzoyl-1-piperazinyl]oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 153213-40-2 CAPLUS

CN Carbamic acid, [5-[[[4-(2-furanylcarbonyl)-1-piperazinyl]oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 153213-41-3 CAPLUS


CN Carbamic acid, [5-[[[4-[(diethylamino)carbonyl]-1-piperazinyl]oxy]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 153213-42-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, phenyl ester (9CI) (CA INDEX NAME)

Delacroix



L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2001 ACS
GI



AB The 2-(alkoxycarbonylamino)-1H-benzimidazole-5-carboxylates I (R = HO, MeO, EtO, PrO, cyclopropylmethoxy, 2-propynyloxy, thienylmethoxy, fluorobenzyloxy, etc.; R1 = Me, Et, Pr, iso-Bu, cyclopropylmethyl) and the 2-(alkoxycarbonylamino)-1H-benzimidazole-5-carboxamides I (R = EtNH, Me2CHNH, Me3CCH2N, piperazino, morpholino, etc.; R1 = Me) were prep'd. from the resp. (alkoxycarbonylamino)-1H-benzimidazole-5-carbonyl chlorides and tested for their antineoplastic and antifilarial activity. Growth inhibition of L1210 cells appeared to be assoc'd. with mitotic cell spindling; the IC50 for growth inhibition of L1210 cells was 0.70 .mu.M for I (R = Me2CHO, R1 = Me) (II). II also had antifilarial activity against *Brugia pahangi*, *litomosoides carni*, and *Acanthocheilonema viteae*.

ACCESSION NUMBER: 1992:83590 CAPLUS
DOCUMENT NUMBER: 116:83590
TITLE: Synthesis and biological activity of certain alkyl 5-(alkoxycarbonyl)-1H-benzimidazole-2-carbamates and related derivatives: a new class of potential antineoplastic and antifilarial agents
AUTHOR(S): Ram, Siya; Wise, Dean S.; Wotring, Linda L.; McCall, John W.; Townsend, Leroy B.
CORPORATE SOURCE: Coll. Pharm., Univ. Michigan, Ann Arbor, MI, 48109-1065, USA
SOURCE: J. Med. Chem. (1992), 35(3), 539-47
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 116:83590


IT 121649-63-6P 121649-64-7P 121649-65-8P
135696-71-8P 135696-72-9P 135696-73-0P
135696-74-1P 135696-75-2P 135696-76-3P
135696-77-4P 135696-78-5P 135696-79-6P
135696-80-9P 135696-81-0P 135720-68-2P
135891-47-3P 135891-48-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antineoplastic and antifilarial activity of)

RN 121649-63-6 CAPLUS


09/676,032

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 121649-64-7 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 121649-65-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, propyl ester (9CI) (CA INDEX NAME)



RN 135696-71-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 135696-72-9 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, propyl

Delacroix

09/676,032


ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 135696-73-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)




RN 135696-74-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-methylbutyl ester (9CI) (CA INDEX NAME)



RN 135696-75-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 135696-76-3 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)


Delacroix

09/676,032




RN 135696-77-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-propynyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)



RN 135696-79-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
(4-fluorophenyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 135696-80-9 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-thienylmethyl ester (9CI) (CA INDEX NAME)


Delacroix

09/676,032



RN 135696-81-0 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135720-68-2 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(1-pyrrolidinyl)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135891-47-3 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 135891-48-4 CAPLUS

Delacroix

09/676,032

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
(4-fluorophenyl)methyl ester (9CI) (CA INDEX NAME)




IT 121649-66-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. and antineoplastic and antifilarial activity of)


RN 121649-66-9 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-methylethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2001 ACS

GI



AB Me 5(6)-alkoxycarbonylbenzimidazole-2-carbamates I (R = Me, Et, Pr, CHMe₂, Bu, CH₂CHMe₂) and 5(6)-carboxyl analog I (R = H) and its salts I (R = Na, centperazine) were synthesized starting from 4-amino-3-nitrobenzoic acid. The drugs were tested for their anthelmintic activity in rodents infested by *Ancylostoma ceylanicum*, *Syphacia obvelata*, *Nippostrongylus brasiliensis*, *Hymenolepis nana*, *Cysticercus fasciolaris*, *Litomosoides carinii* and *Dipetalonema viteae* and found to cause 100% elimination of *A. ceylanicum* hookworms at an oral dose of 25-250 mg/kg but not so effective against other helminths.

ACCESSION NUMBER: 1989:457629 CAPLUS

DOCUMENT NUMBER: 111:57629


TITLE: Studies in antiparasitic agents. Part 9. Synthesis of 5(6)-(alkoxycarbonyl)-2-substituted-benzimidazoles as potential anthelmintics

AUTHOR(S): Naim, S. Shawkat; Singh, Sudhir K.; Sharma, Satyavan; Gupta, Suman; Fatma, N.; Chatterjee, R. K.; Katiyar,


Delacroix

09/676,032


CORPORATE SOURCE: J. C.
Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, 226
001, India
SOURCE: Indian J. Chem., Sect. B (1988), 27B(12), 1106-9
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:57629
IT 121649-63-6P 121649-64-7P 121649-65-8P
121649-66-9P 121649-67-0P 121649-68-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antiparasitic activity of)
RN 121649-63-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, methyl
ester (9CI) (CA INDEX NAME)



RN 121649-64-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, ethyl
ester (9CI) (CA INDEX NAME)




RN 121649-65-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, propyl
ester (9CI) (CA INDEX NAME)




RN 121649-66-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
1-methylethyl ester (9CI) (CA INDEX NAME)

09/676,032




✓

RN 121649-67-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, butyl ester (9CI) (CA INDEX NAME)



✓

RN 121649-68-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



✓



L20 ANSWER 23 OF 69 HCAPLUS COPYRIGHT 2001 ACS

AN 1992:251202 HCAPLUS

DN 116:251202

TI Synergistic effects of photoactivated tetra(4-sulfonatophenyl)porphine and nocodazole on microtubule assembly, accumulation of cells in mitosis and cell survival

AU Berg, Kristian; Steen, Harald B.; Winkelman, James W.; Moan, Johan

CS Dep. Biophys., Inst. Cancer Res., Oslo, N-0310, Norway

SO J. Photochem. Photobiol., B (1992), 13(1), 59-70


CODEN: JPPBEG; ISSN: 1011-1344

DT Journal

LA English


AB Human carcinoma cells of the line NHIK 3025 were incubated with meso-tetra(4-sulfonatophenyl)porphine (TPPS4) for 18 h and exposed to light in the absence or presence of nocodazole. Nocodazole (1 μ g/mL) was applied to the cells 15 min prior to light exposure and washed off the cells immediately afterwards. The presence of nocodazole during photoactivation of TPPS4-loaded cells leads to a significantly reduced ability of tubulin to repolymerize after withdrawal of nocodazole, an increased accumulation of the cells in mitosis with a larger fraction in c-metaphase and a higher yield of photoactivated cells. A higher proportion of the cells accumulating in mitosis 6-12 h after exposure to light is unable to form colonies when exposed to light in the presence of nocodazole than in its absence. The present results are consistent with a specific TPPS4-induced photodamage to the unpolymerized form of the

CN Carbamic acid, [5-[(dimethylamino)carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 67476-48-6 HCAPLUS

CN Carbamic acid, [5-[(ethylamino)carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 89791-14-0 HCAPLUS

CN Carbamic acid, [5-[[4-(4-fluorophenyl)amino]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 121649-63-6 HCAPLUS

✓ CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 121649-64-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 121649-65-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, propyl ester (9CI) (CA INDEX NAME)



RN 135696-71-8 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135696-72-9 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, propyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 135696-73-0 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, cyclopropylmethyl ester (9CI) (CA INDEX NAME)




RN 135696-74-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3-methylbutyl ester (9CI) (CA INDEX NAME)




RN 135696-75-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 135696-76-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 135696-77-4 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-propynyl ester (9CI) (CA INDEX NAME)




RN 135696-78-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 3,5,5-trimethylhexyl ester (9CI) (CA INDEX NAME)



RN 135696-79-6 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, (4-fluorophenyl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 135696-80-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, 2-thienylmethyl ester (9CI) (CA INDEX NAME)



RN 135696-81-0 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135696-82-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(ethoxycarbonyl)amino]-, ethyl ester, hydrochloride (2:1) (9CI) (CA INDEX NAME)




1/2 HCl

RN 135696-85-4 HCAPLUS


CN Carbamic acid, [5-[(1-methylethyl)amino]carbonyl]-1H-benzimidazol-2-yl]-, hydrochloride (2:1) (9CI) (CA INDEX NAME)

methyl ester (9CI) (CA INDEX NAME)




RN 135696-86-5 HCAPLUS

CN Carbamic acid, [5-[[[(2,2-dimethylpropyl)amino]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 135696-87-6 HCAPLUS


CN Carbamic acid, [5-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 135696-88-7 HCAPLUS

CN Carbamic acid, [5-(1-piperazinylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 135696-89-8 HCAPLUS

CN Carbamic acid, [5-[[4-[(dimethylamino)carbonyl]-1-piperazinyl]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 135696-90-1 HCAPLUS

CN Carbamic acid, [5-[[4-[(diethylamino)carbonyl]-1-piperazinyl]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 135696-91-2 HCAPLUS

CN Carbamic acid, [5-[(3-fluorobenzoyl)amino]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 135696-92-3 HCAPLUS

CN Carbamic acid, [5-[(4-fluorobenzoyl)amino]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 135696-93-4 HCAPLUS

CN Carbamic acid, [5-[(2-fluorobenzoyl)amino]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 135720-68-2 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)



● HCl


RN 135720-69-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(1-methylethoxy)carbonyl]amino]-,
1-methylethyl ester (9CI) (CA INDEX NAME)




RN 135891-47-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 135891-48-4 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]-,
(4-fluorophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 135891-49-5 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(ethoxycarbonyl)amino]-, ethyl
ester (9CI) (CA INDEX NAME)

8



RN 135891-50-8 HCAPLUS

CN Carbamic acid, [5-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




IT 65003-40-9P 135696-70-7P

(prepn. and chlorination and amidation or esterification and antineoplastic and antifilarial activity of)


RN 65003-40-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(methoxycarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 135696-70-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(ethoxycarbonyl)amino]- (9CI) (CA INDEX NAME)



IT 135696-94-5P

(prepn. and esterification of)

RN 135696-94-5 HCAPLUS

CN Carbamic acid, [5-(chlorocarbonyl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

microtubule components.

IT 31430-18-9, Nocodazol

(photosensitization by, of human carcinoma cells to light,
tetrasulfonatophenylporphine synergistic effect on microtubule assembly
and cell cycle in)

RN 31430-18-9 HCAPLUS

CN Carbamic acid, [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]-, methyl ester
(9CI) (CA INDEX NAME)

